Abstract
Arterial calcification due to deficiency of CD73 (ACDC) is a rare genetic calcification disorder. Recently, a pilot study was conducted which utilized etidronate, a bisphosphonate, to treat ACDC. The results of this study indicated a significant effect on slowing arterial calcification and disease progression in a cohort of affected individuals, thereby favoring the use of etidronate as a potential treatment option for this disease. This would mark etidronate to possibly become the first standard treatment for this rare, vascular disorder. Although further research is needed to prove its efficacy, this landmark study symbolizes a step in the right direction and underscores the need for continued investigation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
